reports
- Do Kim
Water Tower Hour Recap: OvaWatch Update
CEO and Director Nicole Sandford joined us on the Water Tower Hour to discuss the latest on OvaSuite, Aspira’s portfolio of non-invasive tests for the risk assessment of ovarian cancer, in addition to the opportunities for the product pipeline and biobank. Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are available in our full report. OvaWatch mass monitoring completes OvaSuite portfolio. With the recent launch of longitudinal or serial adnexal ...
- Sally Yanchus
Water Tower Hour Recap: CEO Nicole Sandford Discusses Aspira's Diagnos...
CEO and Director Nicole Sandford joined us on the Water Tower Hour to discuss Aspira’s suite of non-invasive tests to aid in the diagnosis of gynecologic diseases. Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Sandford talked about her experience at Aspira, which began as an investor in 2019. She was asked to join the board and became CEO in 2022. Sandford was very impressed with Aspira’s simple blood test for risk assessment of ovarian cancer. OvaWa...
- Sally Yanchus
Aspira Women's Health Reports Full-Year 2023 Results
AWH reported full-year 2023 results, mostly in line with our estimates. Full-year 2023 revenue was $9.2 million, a 15% increase from 2022, and slightly below our $9.6 million estimate. Good expense control continued throughout the year, resulting in better-than-expected EPS of ($1.81), compared with our ($1.94) estimate. Our 2024 revenue estimate reflects annual growth of 20% to $11 million, slightly below our prior estimate, while our 2024 EPS estimate is ($1.55), as good cost control continues...
- Sally Yanchus
Aspira Women's Health Expands Senior Leadership Team
Aspira Women’s Health expands senior management team with the addition of Sandra Milligan, MD, JD as President effective April 1, 2024. Dr. Milligan will report to CEO Nicole Sandford. She has more than 25 years of experience in the healthcare sector, with corporate experience that includes executive roles at biopharmaceutical companies Amgen, Genentech, Merck, and Organon. Dr. Milligan supported pipeline and product development in both oncology and non-oncology disease areas, with recent emphas...
- Sally Yanchus
Aspira Women's Health Announces OvaSuite Distribution Agreement in the...
Aspira Women’s Health today announced it signed a five-year distribution agreement granting Hi-Precision Laboratories the exclusive right to market and distribute the OvaSuiteSM portfolio of tests in the Philippines. The commercialization of OvaSuite products will commence upon receiving regulatory approval. In consideration of the licenses and rights granted by Aspira, Hi-Precision Laboratories will pay royalties to Aspira for each test performed in the Philippines. Hi-Precision Laboratories is...
- Sally Yanchus
Fireside Chat with Aspira's Chief Scientific Officer and Director of M...
On January 30, WTR hosted a fireside chat with Chief Scientific Officer Dr. Jody Berry and Director of Medical Affairs Dr. Leo Twiggs. This report contains a transcript of the conversation, which can be accessed on demand in our full report. We asked Dr. Berry why he recently joined Aspira and what the next steps are for its OvaSuite portfolio. We also discussed how his research with Dana-Farber and how the incorporation of miRNA could change the use of ovarian cancer tests. Dr. Berry talked abo...
- Sally Yanchus
Aspira Women's Health Hosts R&D Day; Updates on Ovarian Cancer and End...
Aspira Women’s Health hosted an R&D Day and discussed updates on its non-invasive diagnostic platforms for ovarian cancer and endometriosis. CEO Nicole Sandford led the discussion, and was joined by Chief Scientific Officer Dr. Jody Berry, PhD, and one of Aspira’s medical advisors and research partners, Dr. Kevin Elias, MD. Aspira also discussed the domestic market potential for both ovarian cancer and endometriosis products, which it estimates is more than $1.5 billion. For ovarian cancer, t...
- Sally Yanchus
Aspira Women's Health to Host R&D Day on January 4, 2024; Updating Ova...
Aspira Women’s Health announced it will host a virtual R&D Day on January 4, 2024, at 11:00 am ET. The event will feature experts who will present the exciting progress of the company’s product pipeline. Registration link accessible in our full report. The event will be hosted by CEO Nicole Sandford. She will be joined by Jody Berry, PhD, Chief Scientific Officer for Aspira Women’s Health, and Kevin Elias, MD, Assistant Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Med...
- Sally Yanchus
Provides Important Update on EndoCheck Diagnostic Test
Aspira Women’s Health announced today that it has completed the design of the EndoCheck test based on the analysis of samples received from The University of Oxford in October. This data shows EndoCheck to be a high-performing blood test for localized endometriosis, including ovarian endometriosis masses known as endometrioma. Endometrioma is a localized form of endometriosis that has formed an ovarian mass. It is one of the most common types of endometriosis. All endometriosis, including end...
- Sally Yanchus
Secures Important Reimbursements
Aspira Women’s Health made two reimbursement announcements this week. On November 27, Aspira announced that the Centers for Medicare and Medicaid Services (CMS) approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1. Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024. “Crosswalking” refers to a process for setting...
- Sally Yanchus
Reports 3Q23 Results
Aspira Women’s Health reported 3Q23 financial results, mostly in line with our estimates. Revenue of $2.2 million was below our estimate, but good expense control is in place and is expected to continue. Our estimates for 2023 and 2024 remain in line with our prior estimates. Aspira said it hired a business development (BD) executive in the quarter who will expand on the company’s current commercial expansion plans. The BD effort will focus on building partnerships with large health systems, MD ...
- Sally Yanchus
Two Important Announcements from Aspira Women's Health
On October 25, Aspira Women’s Health announced that a poster on its in-development miRNA-based ovarian cancer test was presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Ovarian Cancer. The poster, titled, “Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model,” highlighted data showing miRNA’s potential to improve the diagnostic accuracy of non-invasive diagnostic tests. The study showed that the...
- Sally Yanchus
Fireside Chat with CFO Torsten Hombeck
Fireside chat with CFO Torsten Hombeck. On September 7, 2023, we held a fireside chat with AWH’s CFO Torsten Hombeck. We discussed several topics. Hombeck recently joined AWH, and we talked about what drew him to the company. He saw the very large commercial market opportunity for AWH’s diagnostic tests and for him, this has significant market potential. It serves an unmet market need, since the only other way to diagnose ovarian cancer is an invasive procedure to remove the ovaries. We also dis...
- Sally Yanchus
Announces New Chief Scientific Officer
Aspira Women’s Health announced it has named Jody Berry, Ph.D as its new Chief Scientific Officer. Dr. Ryan Phan, who stepped down from the position, remains as an advisor through the end of the year to help with the transition and provide scientific and operational advice related to ongoing product development programs. Dr. Berry is a recognized international expert in immunoassay development, antibody technology, and infectious diseases. Dr. Berry joins AWH from OraSure Technologies, Inc. w...
- Sally Yanchus
Signs Exclusive Agreement with University of Oxford
Agreement with University of Oxford. On August 31, 2023, Aspira Women’s Health announced that it has entered into a material transfer agreement with the University of Oxford for the procurement of serum samples to be used to verify and validate AWH’s endometriosis blood testing algorithms. This means that AWH will be able to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis. Verifying the test. This involves taking a te...
- Sally Yanchus
Reports In-Line 2Q23
Aspira Women’s Health reported in-line 2Q23 financial results. Revenues in the quarter were $2.5 million, below our estimate of $3.2 million. EPS for the quarter was ($0.28), above our estimate of ($0.66). AWH continues its good expense control, showing its ability to continue to grow revenue and test volumes, while keeping expenses well under control. 2Q23’s gross margin was 62% versus 47% a year ago, and operating loss for the quarter was ($4.3 million), a significant improvement from 2Q22’s...
- Sally Yanchus
Fireside Chat with CEO Nicole Sandford
CEO Nicole Sandford joined us for a fireside chat on June 21. We discussed AWH’s mission to transform women’s health, the diagnostic tools that AWH offers to gynecologists, and why these tools are important to patients, physicians, and payers. This report contains a transcript of the conversation, which can be accessed on demand or in the full report. AWH has a unique product and a solid business plan. The company has developed markets and innovative testing solutions that improve gynecologic he...
- Sally Yanchus
Publication of Three Abstracts by ASCO Supports OvaSuite Ovarian Cance...
Aspira Women's Health announced the publication of three abstracts at the American Society of Clinical Oncology (ASCO) meeting today. The abstracts were co-authored by AWH's Health Innovation Team and Dr. Gerard Reilly, Director of Clinical Research and Innovation at Axia Women's Health. These abstracts support the clinical efficacy of the newly released OvaWatch by confirming OvaWatch as an industry-leading ovarian cancer risk assessment test that can safely reduce premature surgeries in the ma...
- Sally Yanchus
OvaWatch is Here; Watch Out!
Aspira Women's Health (AWH) hosted an Investor Day on May 23, which focused on its OvaWatchSM and EndoCheckTM diagnostic tools. Two clinicians, Dr. Kevin Elias of Harvard Medical School, and Dr. Tamika Sea of Piedmont Henry Hospital in Atlanta, spoke to investors about their experience with AWH's diagnostic technology. OvaWatch, currently on the market, is a very important tool in monitoring and determining suspicious adnexal masses (indeterminate masses that show up on pelvic ultrasound scans)....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.